PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 03rd Jul 2013 09:16

Aberdeen Asset Management: Bank of America reduces target price from 410p to 360p maintaining an underperform rating.ARM Holdings: UBS upgrades to buy from neutral, keeps target price at 970p.Cineworld: Investec ups target price from 347p to 360p and keeps a buy recommendation. N+1 Singer moves target price from 340p to 357p retaining a hold recommendation.Diageo: Espirito Santo cuts target price from 2280p to 2250p, while leaving its buy recommendation unchanged.Domino's Pizza Group: Canaccord Genuity reduces target price to 550p and downgrades to sell. Numis cuts view to add from buy. Oriel lowers to hold from add.Inchcape: Nomura takes target price from 485p to 500p staying with its neutral rating.Northgate: Goldman Sachs moves target price from 340p to 370p maintaining a neutral rating.Ocado: Jefferies raises target price from 80p to 275p, while keeping its hold recommendation.office2office: Panmure Gordon reduces target price from 120p to 67p and downgrades from buy to hold.Ophir Energy: HSBC Holdings increases target price from 530p to 558p reiterating an overweight rating.Persimmon: Deutsche Bank raises target price from 1060p to 1202p and stays with a hold recommendation. Goldman Sachs ups target price from 1756p to 1811p retaining a strong buy recommendation.PZ Cussons: Canaccord Genuity raises target price to 440p and upgrades from sell to buy.Randgold Resources: Citi increases target price from 3926p to 4491p and maintains a neutral rating.Reckitt Benckiser: Espirito Santo takes target price from 4140p to 4160p, but still recommends selling.SAB Miller: Espirito Santo reduces target price from 3520p to 3360p keeping a neutral rating.Serco Group: HSBC Holdings raises target price from 590p to 670p and upgrades to neutral.Smith (DS): Goldman Sachs lowers target price from 278p to 261p reiterating a neutral rating.Spirent Communications: Investec places both its target price (prev.: 150p) and its buy recommendation under review. Panmure Gordon moves target price from 176p to 166p, while its buy recommendation remains unchanged.Stagecoach: Morgan Stanley ups target price from 310p to 330p and retains an equal-weight rating.Summit Corporation: N+1 Singer shifts target price from 9p to 8.80p keeping a buy recommendation.Super Group: Investec increases target price from 843p to 878p leaving its buy recommendation unaltered.UNITE Group: JP Morgan moves target price from 425p to 450p and keeps an overweight rating.
More News
15 Dec 2016 12:38

Summit Therapeutics widens loss as drug development continues

(ShareCast News) - Drug discovery and development company Summit Therapeutics posted its financial results for the third quarter to 31 October on Thursday. The AIM-traded firm had cash and cash equivalents at period end of £34.6m compared to £16.3m on 31 January. Its loss for the nine months was £1

Read more
16 Nov 2016 12:28

Summit Therapeutics enrols first US patients in ezutromid trial for DMD

(ShareCast News) - AIM-listed drug discovery and development company Summit Therapeutics has enrolled its first patients in phase II proof of concept trials in the US of ezutromid in patients with Duchenne muscular dystrophy. Summit said enrolment and dosing of patients into Phase Out DMD in the UK

Read more
6 Oct 2016 14:28

Summit Therapeutics shares plummet despite positive progress

(ShareCast News) - Drug discovery and development company Summit Therapeutics presented preclinical data at the 21st International Congress of the World Muscle Society in Granada, Spain on Thursday, including further findings from its programme to develop tools to measure biomarkers of muscle health

Read more
4 Oct 2016 11:52

BUZZ-Summit Therapeutics: Best day since 2009 on Sarepta deal

** Shares in drug developer Summit Therapeutics up 58 pct after teams up with US drug co Sarepta Therapeutics to develop and market DMD drug in Europe ** Stock poised for its best day since April 2009 ** Co gets $40 mln upfront payment, could receive up to $522 million in milestone p

Read more
9 Aug 2016 11:51

Summit Therapeutics Sees Positive Phase I Trial Results For Ezutromid

Read more
21 Jun 2016 06:46

Summit Therapeutics Shows Further Positive Trial Data For Ridinilazole

Read more
17 Jun 2016 11:21

Summit Therapeutics Enrols First Patient In Phase II Ezutromid Trial

Read more
2 Jun 2016 14:30

Cash reduced, losses widen at Summit Therapeutics

(ShareCast News) - Drug discovery and development company Summit Therapeutics posted its first quarter results on Thursday, with cash reduced and losses widening. The AIM-traded firm, which is advancing therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI), had cash and ca

Read more
10 May 2016 16:46

Losses widen at Summit Therapeutics

(ShareCast News) - Drug discovery and development company Summit Therapeutics reported an increase in cash and activities in its full-year results on Tuesday, though its losses widened as it carried its projects towards commercialisation. The AIM-traded firm had cash and cash equivalents of £16.3m o

Read more
10 May 2016 11:20

Summit Therapeutics Posts Widened Loss As It Progresses Programmes

Read more
28 Apr 2016 11:11

Summit Therapeutics Gets Further US Patent For Antibiotic Ridinlazole

Read more
26 Apr 2016 11:16

Summit Therapeutics Gets Clearance To Expand Ezutromid Trial To US

Read more
30 Mar 2016 12:48

Summit reports positive results from Duchenne muscular dystrophy treatment

(ShareCast News) - Summit Therapeutics reported positive interim findings on Wednesday, from a recent Phase 1 trial of a new oral formulation of its SMT C1100 therapy for Duchenne muscular dystrophy. The AIM-traded drug discovery and development company focuses on advancing therapies for Duchenne mu

Read more
30 Mar 2016 11:06

Summit Therapeutics Gets Positive Interim SMT C1100 Test Results

Read more
7 Mar 2016 12:43

Summit Therapeutics Sees Further Positive Data For Ridinilazole

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.